The investigation centers on claims that Soleno Therapeutics failed to disclose significant safety concerns regarding DCCR, a treatment intended for Prader-Willi syndrome and hyperphagia. According to a federal securities lawsuit, the company allegedly concealed evidence of excess fluid retention observed in trial participants. These omissions suggest that the drug carried materially greater risks than previously communicated to the market.

Legal representatives argue that these undisclosed risks have compromised the commercial viability of DCCR. Potential consequences for the company include reduced patient adoption, prescriber reluctance, and possible regulatory intervention. Investors who purchased SLNO stock prior to March 26, 2025, are being urged to contact Sophia Anne Silayan at Kuehn Law to discuss potential rights and claims. The firm operates on a contingency basis, covering all case costs for participating investors.